Cargando…

A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema

PURPOSE: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). METHODS: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhiqing, Chen, Binbin, Hu, Peike, Liu, Haipeng, Zheng, Dingchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577862/
https://www.ncbi.nlm.nih.gov/pubmed/37846386
http://dx.doi.org/10.1016/j.aopr.2022.100051
_version_ 1785121399975706624
author Chen, Zhiqing
Chen, Binbin
Hu, Peike
Liu, Haipeng
Zheng, Dingchang
author_facet Chen, Zhiqing
Chen, Binbin
Hu, Peike
Liu, Haipeng
Zheng, Dingchang
author_sort Chen, Zhiqing
collection PubMed
description PURPOSE: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). METHODS: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 ​h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P ​< ​0.05 was considered statistically significant. RESULTS: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ​± ​12.47 and 79.50 ​± ​10.85, maximal retinal thickness in macular area was 390.95 ​± ​77.12 ​μm and 354.13 ​± ​55.03 ​μm, average retinal thickness in macular area was 334.25 ​± ​36.45 ​μm and 314.31 ​± ​33.28 ​μm, foveal thickness was 287.00 ​± ​46.79 ​μm and 265.63 ​± ​67.14 ​μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P ​< ​0.05). All follow-up results of foveal thickness were not significantly different (P ​> ​0.05) from the baseline result, except that in the 6th month (P ​= ​0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. CONCLUSIONS: PBM is a safe and effective treatment of DME, which deserves further investigation.
format Online
Article
Text
id pubmed-10577862
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105778622023-10-16 A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema Chen, Zhiqing Chen, Binbin Hu, Peike Liu, Haipeng Zheng, Dingchang Adv Ophthalmol Pract Res Full Length Article PURPOSE: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). METHODS: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26–68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 ​h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P ​< ​0.05 was considered statistically significant. RESULTS: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 ​± ​12.47 and 79.50 ​± ​10.85, maximal retinal thickness in macular area was 390.95 ​± ​77.12 ​μm and 354.13 ​± ​55.03 ​μm, average retinal thickness in macular area was 334.25 ​± ​36.45 ​μm and 314.31 ​± ​33.28 ​μm, foveal thickness was 287.00 ​± ​46.79 ​μm and 265.63 ​± ​67.14 ​μm. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P ​< ​0.05). All follow-up results of foveal thickness were not significantly different (P ​> ​0.05) from the baseline result, except that in the 6th month (P ​= ​0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. CONCLUSIONS: PBM is a safe and effective treatment of DME, which deserves further investigation. Elsevier 2022-04-26 /pmc/articles/PMC10577862/ /pubmed/37846386 http://dx.doi.org/10.1016/j.aopr.2022.100051 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Full Length Article
Chen, Zhiqing
Chen, Binbin
Hu, Peike
Liu, Haipeng
Zheng, Dingchang
A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
title A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
title_full A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
title_fullStr A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
title_full_unstemmed A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
title_short A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
title_sort preliminary observation on rod cell photobiomodulation in treating diabetic macular edema
topic Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577862/
https://www.ncbi.nlm.nih.gov/pubmed/37846386
http://dx.doi.org/10.1016/j.aopr.2022.100051
work_keys_str_mv AT chenzhiqing apreliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT chenbinbin apreliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT hupeike apreliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT liuhaipeng apreliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT zhengdingchang apreliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT chenzhiqing preliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT chenbinbin preliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT hupeike preliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT liuhaipeng preliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema
AT zhengdingchang preliminaryobservationonrodcellphotobiomodulationintreatingdiabeticmacularedema